Cora Sternberg is a Prostate Cancer Treatment and Research physician affiliated with Cornell University. OpenAlex indexes 954 publications with 73,928 citations (h-index 110); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Cora Sternberg, MD, is affiliated with Cornell University. The public record shows 954 publications with 73,928 citations (h-index 110), centered on Prostate Cancer Treatment and Research, Bladder and Urothelial Cancer Treatments, Renal cell carcinoma treatment. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 22 companies, 1 NIH-funded awards (2021–2025).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Prostate Cancer Treatment and Research
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 31 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 436.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Sponsor: Weill Medical College of Cornell University
Industry payments
Updated 14 Oct 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202511 payments
- TOLMAR, INC.Program year20254 payments
- PFIZER INC.Program year20252 payments
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Gonadotropin Releasing Hormone Receptor Agonist100%Leuprolide acetate100%Part B, office-administered≥19 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- The joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles
Weill Medical Coll of Cornell Univ
FY2025$380,595U24CA264032 - The joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles
Weill Medical Coll of Cornell Univ
FY2024$385,514U24CA264032 - The joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles
Weill Medical Coll of Cornell Univ
FY2023$397,689U24CA264032
Congress activity
Updated 14 Oct 2026
229 congress contributions (2006–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Changes in CTCAE v6: Effect on dose-escalation and dose-limiting toxicity with repeat analysis of recent clinical trials.
ASCO Annual Meeting
ASCO2026Co-author - Abstract CT127: Pre-operative abemaciclib in localized cisplatin-ineligible MIBC with tissue and ctDNA molecular response validation (CLONEVO)
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.
Prostate cancer and prostatic diseases
Article2026 - Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
Journal of clinical oncology
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyArticle4,597 citations2012
- 02Abiraterone and Increased Survival in Metastatic Prostate CancerArticle4,419 citations2011
- 03Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaArticle3,418 citations2017
- 04Enzalutamide in Metastatic Prostate Cancer before ChemotherapyArticle3,055 citations2014
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/cora-sternberg-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/cora-sternberg-73886118
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/cnsternberg
Mentions by others
where others cite or feature them- Other
news.weill.cornell.edu/people/dr-cora-sternberg
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.weill.cornell.edu ↗ - Other
urotoday.com/video-lectures/esmo-2024/video/4321-event-free-survival-as-surrogate-endpoint-in-muscle-invasive-bladder-cancer-research-cora-sternberg.html
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urotoday.com ↗ - Spotify
open.spotify.com/show/2zE35MXZISmYJI4WDzaCPZ
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →open.spotify.com ↗ - X / Twitter
x.com/WCMGUcancer/status/1929621593719791843
- YouTube
youtube.com/@PrecisionSignals
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Devereux, MD
Cornell University
Thomas Walsh, MD
Cornell University
George Alexopoulos, MD
Cornell University
James Bussel, MD
Cornell University
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)